Mindfulness-Based ADHD Treatment for Children: a Feasibility Study

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

October 29, 2024

Study Completion Date

October 29, 2024

Conditions
Attention Deficit Hyperactivity Disorder
Interventions
BEHAVIORAL

Mindfulness-Based ADHD Treatment for Children

MBAT-C is derived from Mindfulness-Based Stress Reduction (MBSR), a well-known and extensively-studied mindfulness intervention. Unlike all other mindfulness-based interventions, however, MBAT-C is tailored to the needs, abilities, and vulnerabilities of children with ADHD through the use of age-appropriate class length, homework assignments, contemplative practices, and discussion topics.

BIOLOGICAL

Goal-Standard Medication (Treatment as Usual)

"Participants will receive gold-standard, non-experimental medication. This treatment arm relies on a step-by-step approach that is designed to mimic pharmacologic treatment-as-usual in the community. The treatment algorithm is as follows:~1. All participants will start with Concerta; Ritalin may be started if the effect of Concerta wears off mid-day;~2. If Concerta +/- Ritalin is ineffective or not tolerated, participants will progress to Vyvanse; Adderall may be started if the effect of Vyvanse wears off mid-day;~3. If Vyvanse +/- Adderall is also ineffective or not tolerated, participants will progress to Kapvay;~4. If Kapvay is ineffective or not tolerated, participants will progress to Intuniv.~5. Alternative combinations of the above medications will be considered if the above combinations are ineffective or otherwise not tolerated."

Trial Locations (1)

06510

Clinical & Affective Neuroscience Lab, New Haven

All Listed Sponsors
collaborator

National Center for Complementary and Integrative Health (NCCIH)

NIH

lead

Yale University

OTHER

NCT04737512 - Mindfulness-Based ADHD Treatment for Children: a Feasibility Study | Biotech Hunter | Biotech Hunter